Pharvaris

Go sign green light
Biotech

FDA lifts remaining hold on Pharvaris’ HAE drug

The preventative oral med for hereditary angioedema has had its remaining hold lifted weeks after the treatment proved its worth in a phase 2 study.
James Waldron Jan 22, 2024 7:32am
finch canary cage free bird release

Pharvaris oral hereditary angioedema med cuts attacks in phase 2

Dec 6, 2023 10:18am
FDA

Pharvaris runs tox test to reverse clinical hold for HAE asset

Jan 9, 2023 10:42am
parachutes

Ex-Pfizer R&D head Abraham joins Vividion—Chutes & Ladders

Feb 14, 2020 9:30am
Exit sign

Pharvaris nabs Shire exec as new CMO

Feb 7, 2020 9:22am